Sabby Management’s Cellectar Biosciences CLRB Stock Holding History

Sabby Management’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,422	Closed	-$508K	–	187
2021 Q2	$508K	Buy	1,422 +125	+10%	+$54.2K	0.07%	109
2021 Q1	$626K	Sell	1,297 -366	-22%	-$218K	0.12%	97
2020 Q4	$1.04M	Buy	+1,663	New	+$764K	0.2%	51
2017 Q1	–	Sell	-108	Closed	-$395K	–	274
2016 Q4	$395K	Buy	+108	New	+$586K	0.02%	212
2016 Q2	–	Sell	-24	Closed	-$242K	–	301
2016 Q1	$242K	Sell	24 -5	-17%	-$77.4K	0.01%	253
2015 Q4	$633K	Buy	29 +16	+123%	+$679K	0.03%	220
2015 Q3	$751K	Sell	13 -6	-32%	-$546K	0.03%	269
2015 Q2	$1.64M	Sell	19 -3	-14%	-$262K	0.06%	185
2015 Q1	$2.02M	Buy	22 +1	+5%	+$80.3K	0.08%	145
2014 Q4	$1.92M	Sell	21 -3	-13%	-$231K	0.06%	129
2014 Q3	$1.66M	Buy	+24	New	+$2.07M	0.06%	127

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Sabby Management's CLRB Position: Q3 2021 in Review

Sabby Management sold out of Cellectar Biosciences (CLRB) in Q3 2021, closing a stake of 1,422 shares — an estimated $508K sold.

Sabby Management first reported a position in CLRB in Q3 2014 and held it in 11 quarters. The position peaked at $2.02M in Q1 2015. 38 funds tracked by Wall St. Rank hold CLRB as of Q3 2021.

Sabby Management reported no remaining Cellectar Biosciences position as of Q3 2021 after selling out during the quarter.
Sabby Management sold 1,422 Cellectar Biosciences shares in Q3 2021, an estimated $508K.
Sabby Management first reported a position in Cellectar Biosciences in Q3 2014 and held it in 11 quarters.
Sabby Management's Cellectar Biosciences position peaked at $2.02M in Q1 2015.
38 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2021.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.